Cutera $CUTR stock has confirmed a downtrend channel breakout as the stock runs towards its Triangle breakout price target zone ($60 to $65 as shown in green colored rectangle on the chart below).
One of our favorite charting tools is Finviz because of the AI lines drawn on stock charts. In Finviz, you can more clearly see the beautiful Triangle breakout pattern in $CUTR stock.
AviClear National Launch
Cutera announced on November 7, 2022, that AviClear is now widely accessible to medical professionals treating patients across North America. To treat mild, moderate, and severe acne, as well as for the removal of acne scars, AviClear is the first and only energy device to have received approval from both the FDA and Health Canada.
Following its FDA clearance in March 2022, AviClear has attracted significant interest from medical professionals and patients, and Cosmopolitan Magazine recently named it the Best Laser Treatment for Acne. Along with increased accessibility, Cutera is announcing a new, monthly financing plan for US customers with rates beginning at $99 per month.
“I was an early AviClear adopter because I know this treatment will change the way my acne patients face the world,” said Sonia Batra, MD, founder of Batra Dermatology. “I am thrilled my colleagues nationwide will now have access to this device, and I am even happier for their patients who have not wanted or could not proceed with prescription options. What makes the treatment even more appealing is that it can be used on all skin types and acne severities without adverse effects. I have no doubt it will be the treatment of choice for many acne sufferers.”
“We are pleased to see AviClear praised as a groundbreaking treatment by physicians, patients, and the media,” said Dave Mowry, CEO of Cutera. “Pairing the commercial launch with the new patient financing option will enable us to extend the reach of AviClear to more people who want an effective, chemical-free, and durable solution to their acne.
“Based on our market feedback to date, we are confident that patient demand and practice installations will continue to grow over the next several quarters beginning in the first quarter of 2023,” said Mowry. “Affordability, efficacy, and durability will help establish AviClear as the gold standard of care for acne suffers.”
AviClear is now broadly available to physicians and practitioners across the United States, with a limited commercial release in Canada.